

OncoZenge to present BupiZenge™ Phase III at the Pain Therapeutics Summit

OncoZenge AB (publ) (“OncoZenge” or “the Company”) today announces that Marie-Louise Fjällskog, CMO of OncoZenge, will present the Company’s Phase III program for BupiZenge™ at the 20th Annual Pain Therapeutics Summit in the San Francisco Bay Area, USA, on September 28–29.

The Pain Therapeutics Summit is a leading industry event focused on pain therapeutics, translational research, clinical development and non-opioid innovation. The meeting brings together leaders from biotech, pharmaceutical companies, academia, government and clinical research to discuss advances in pain research and the development of new treatments.

Marie-Louise Fjällskog’s presentation will focus on OncoZenge’s Phase III program for BupiZenge™, a novel, locally acting and non-opioid treatment being developed for oral pain caused by oral mucositis in patients undergoing cancer treatment.

“I am very pleased to have the opportunity to present our Phase III program for BupiZenge™ at the Pain Therapeutics Summit. Oral pain remains a major challenge for patients with oral mucositis, and I look forward to sharing our approach and engaging with experts working to advance pain treatment.” - Marie-Louise Fjällskog, Board member and CMO at OncoZenge.

“The Pain Therapeutics Summit provides an important opportunity to present our Phase III program to experts in pain research and drug development. With the Phase III study underway, we look forward to increasing awareness of BupiZenge™ and its potential to address the significant unmet need for effective, non-opioid treatment of oral pain,” - Stian Kildal, CEO of OncoZenge.

BupiZenge™ - Potential to be the leading treatment for oral pain.

Contact

Stian Kildal CEO Mobile: +46 76 115 3797 E-mail: stian.kildal@oncozenge.se

About

OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. The Company recently received European regulatory approval to initiate its pivotal Phase III study 'BEAM-Pain'. The first patient has been enrolled in the trial and site activations are currently ongoing. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit www.oncozenge.se.

OncoZenge AB

Gustavslundsvägen 34, 167 51 Stockholm, Sweden

Certified Adviser

Redeye Nordic Growth AB is the company's Certified Adviser.